Infinity Pharmaceuticals Inc. Presents Data on Retaspimycin Hydrochloride, a Novel Hsp90 Inhibitor, in Non-Small Cell Lung Cancer at American Society of Clinical Oncology Meeting

CHICAGO, June 6, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced encouraging results from a Phase 1b trial of retaspimycin hydrochloride (HCl) (also known as IPI-504), its novel heat shock protein 90 (Hsp90) inhibitor, in combination with docetaxel (also known as Taxotere®) in patients with non-small cell lung cancer (NSCLC).